The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
The US Food and Drug Administration has approved aficamten (Myqorzo) for the treatment of adults with…
The US Food and Drug Administration has approved aficamten (Myqorzo) for the treatment of adults with…